Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic peptide | Melanocortin receptor agonist family |
| Molecular weight | Approximately 1025 Da | Free base form |
| Appearance | White to off-white powder | Lyophilized product |
| Solubility | Soluble in water | Also dissolves in polar organic solvents |
| Storage temperature | -20 degrees Celsius | Dry and protected from light |
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
From this revolution, the 1950s also saw the advent of paper chromatography, reversed-phase partition chromatography (RPC), and hydrophobic interaction chromatography (HIC). The first gels for use in LC were created using cross-linked dextrans (Sephadex) in an attempt to realize Synge's prediction that a unique single-piece stationary phase could provide an ideal chromatographic solution. In the 1960s, polyacrylamide and agarose gels were created in a further attempt to create a single-piece stationary phase, but the purity of and stability of available components did not prove useful for implementation in the HPLC. In this decade, affinity chromatography was invented, an ultra-violet (UV) detector was used for the first time in conjunction with LC, and, most importantly, the modern HPLC was born. Csaba Horvath led the development of modern HPLC by piecing together laboratory equipment to suit his purposes. In 1968, Picker Nuclear Company marketed the first commercially available HPLC as a “Nucleic Acid Analyzer.” The following year, the first international symposia on HPLC was held, and Kirkland at DuPont was able to functionalize controlled porosity pellicular particles for the first time. The 1970s and 1980s witnessed a renewed interest in separations media with reduced interparticular void volumes. Perfusion chromatography showed, for the first time, that chromatography media could support high flow rates without sacrificing resolution. Monoliths aptly fit into this new class of media, as they exhibit no void volume and can withstand flow rates up to 9mL/minute.
17 February Freud under Analysis, historian Peter Gay; psychiatrist Joseph Wortis; the Freud Museum in north-west London; his friend Josef Breuer; his 1895 book Studies on Hysteria; psychologist Frank Sulloway; psychology writer Jeffrey Moussaieff Masson; psychiatrist Jacob Arlow; his 1905 Three Essays on the Theory of Sexuality; the Berlin Psychoanalytic Institute opened in 1920, and he had founded the Deutsche Psychoanalytische Gesellschaft; Abraham Brill; in October 1952 psychologist Hans Eysenck wrote in the Journal of Consulting and Clinical Psychology; Hungarian psychiatrist Thomas Szasz; the Yale Child Study Center; psychologist Jerome Kagan; Francis Crick disputed Freud; Freud moved to England in 1938. A US production, produced by Ben Gooder, directed by Susanne Simpson, made by WGBH and Uden Associates 23 July Mission to Mars, astrogeologist Harold Masursky; Carol Stoker from NASA Ames; planetary geologist Alfred McEwen; German Jesco von Puttkamer and how the space station would be ready by 1994; Gentry Lee of JPL; Jonathan Eberhart and his song about the atmosphere of Mars. Narrated by Martin Jarvis, produced by Patrick Uden, made by Uden Associates 30 July Playing with Fire, about the Bradford City stadium fire on Saturday 11 May 1985; it featured the Woolworths fire of 8 May 1979, in central Manchester. Produced by Michael Blakstad, directed by Patrick Fleming, made by Workhouse Productions
When the particles either pass through each other without interaction or elastically repel during the collision, the gained kinetic energy (related to speed) begins to revert into potential energy, driving the collided particles apart. The decelerating particles will return to the initial distance and beyond into infinity, or stop and repeat the collision (oscillation takes place). This shows that the system, which loses no energy, does not combine (bind) into a solid object, parts of which oscillate at short distances. Therefore, to bind the particles, the kinetic energy gained due to the attraction must be dissipated by resistive force. Complex objects in collision ordinarily undergo inelastic collision, transforming some kinetic energy into internal energy (heat content, which is atomic movement), which is further radiated in the form of photons – the light and heat. Once the energy to escape the gravity is dissipated in the collision, the parts will oscillate at a closer, possibly atomic, distance, thus looking like one solid object. This lost energy, necessary to overcome the potential barrier to separate the objects, is the binding energy. If this binding energy were retained in the system as heat, its mass would not decrease, whereas binding energy lost from the system as heat radiation would itself have mass. It directly represents the "mass deficit" of the cold, bound system. Closely analogous considerations apply in chemical and nuclear reactions.
The gateway hypothesis states that cannabis use increases the probability of trying "harder" drugs. The hypothesis has been hotly debated as it is regarded by some as the primary rationale for the United States prohibition on cannabis use. A Pew Research Center poll found that political opposition to marijuana use was significantly associated with concerns about the health effects and whether legalization would increase cannabis use by children. Some studies state that while there is no proof for the gateway hypothesis, young cannabis users should still be considered as a risk group for intervention programs. Other findings indicate that hard drug users are likely to be poly-drug users, and that interventions must address the use of multiple drugs instead of a single hard drug. Almost two-thirds of the poly drug users in the 2009–2010 Scottish Crime and Justice Survey used cannabis. The gateway effect may appear due to social factors involved in using any illegal drug. Because of the illegal status of cannabis, its consumers are likely to find themselves in situations allowing them to acquaint with individuals using or selling other illegal drugs. Studies have shown that alcohol and tobacco may additionally be regarded as gateway drugs; however, a more parsimonious explanation could be that cannabis is simply more readily available (and at an earlier age) than illegal hard drugs.
=== Hypotheses on image origin === Numerous experimental attempts have reproduced individual characteristics of the Shroud's image on linen. At the same time, no method has yet been shown to replicate all of its macroscopic and microscopic properties simultaneously. As a result, the exact 14th century image-formation mechanism remains debated and unclear.
Sources: en.wikipedia.org
says that none will be opened after the Cleves, Ohio, location, failed their expectations and closed in September 2024 after opening in February of the previous year. In 2025, Roy Rogers will open a third location in Leesburg, Virginia, where it has already has a strong presence as well as one in Cherry Hill, New Jersey.
A myxoma (New Latin from Greek muxa 'mucus') is a myxoid tumor of primitive connective tissue. It is most commonly found in the heart (and is the most common primary tumor of the heart in adults) but can also occur in other locations.
== History == Pyridoxine was discovered in 1934, isolated in 1938, and first made in 1939. It is on the World Health Organization's List of Essential Medicines. Pyridoxine is available both as a generic medication and over the counter product. Foods, such as breakfast cereal have pyridoxine added in some countries.
=== Bacara Club === Peters no longer holds an ownership stake in the Miami Beach nightclub Bacara Club, which opened in April 2026. Having sold his share in the venue, he said: "I already made my bag, I flipped it.. I do not have any ownership anymore.. it is funny though.. they thought me not being there.. did they actually think the club is gonna work without me but it's all good, I made my bag."
=== Fraudulent products during the COVID-19 outbreak === During the COVID-19 pandemic in the United States, the FDA and Federal Trade Commission (FTC) warned consumers about marketing scams of fraudulent supplement products, including homeopathic remedies, cannabidiol products, teas, essential oils, tinctures and colloidal silver, among others. By August 2020, the FDA and FTC had issued warning letters to dozens of companies advertising scam products, which were purported "to be drugs, medical devices or vaccines. Products that claim to cure, mitigate, treat, diagnose or prevent disease, but are not proven safe and effective for those purposes, defraud consumers of money and can place consumers at risk for serious harm"
Sources: en.wikipedia.org
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.
It emerged from research on melanotan II. Investigators exploring derivatives observed distinct pharmacological features related to sexual function.
Common names include bremelanotide and PT-141. Chemical databases may also list early development codes and descriptive names.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.